including the development, production and supply of diagnostic and therapeutic radiopharmaceuticals and radioisotopes.
View moreRelying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
Relying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
We are developing a series of molecularly targeted products for the diagnosis and treatment of cancer, that will redefine the next generation of radiopharmaceuticals based on product and technology innovations.
View more
The premier global event in nuclear medicine and molecular imaging—the 2026 Society of Nuclear Medicine and Molecular Imaging (2026 SNMMI) Annual Meeting—is about to take place in Los Angeles.
View moreReliance Global Group Completes Transformative Investment in Late-Stage Radiopharmaceutical Innovator Innervate Through EZRA’s Biotech Division
PharmaLogic Expands Radiopharmaceutical Footprint With New Atlanta Facility
New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
TLX101-Px (Pixlumi®) MAA Accepted in Europe
SNMMI Image of the Year: New Immuno-PET Tracer Superior to FDG PET in Predicting PD-L1 Expression in Head and Neck Cancer
